

# Predictive Kit to identify patients non responding to platinum therapy



National Cancer Institute  
Aviano (PN) - Italy

## Overview

*“Platinum agents comprise...in 80% of clinical anticancer regimens as a single agent or combined with other anticancer drugs.” (Ref. 1)*

*“Development of platinum-resistant tumor recurrences unfortunately represents a very frequent event.” (Pub. \*)*

*Estimated costs for the adjuvant treatment of colorectal cancer with oxaliplatin-free treatment (about 4500 \$) are 2-3 times lower than treatment including oxaliplatin. (Ref. 2)*

Formulation	clinical use	Cancer type
<i>cisplatin</i>	worldwide	Testicular cancer, ovarian cancer, bladder cancer, head and neck cancer, NSCLC, SCLC, gastric cancer, anal cancer
<i>carboplatin</i>	worldwide	Ovarian cancer, NSCLC, SCLC, melanoma, head and neck cancer, thymic cancer, breast cancer
<i>oxaliplatin</i>	worldwide	Colorectal cancer

(Ref. 1)

cancer type	estimated new cases/year in the USA
<i>breast</i>	268600
<i>colorectal</i>	145600
<i>bladder</i>	80470
<i>ovarian cancer</i>	22500





(Ref. 3-4)

### References:

- X. Kang, et al., Advances in drug delivery system for platinum agents based combination therapy. *Cancer Biol. Med.* 12, 362–374 (2015) DOI: 10.7497/j.issn.2095-3941.2015.0063
- Hasan Nadeem, et al., Cost Differential of Chemotherapy for Solid Tumors. *Journal of Oncology Practice* 12, no. 3, 251-251 (2016) DOI: 10.1200/JOP.2015.006700
- <https://www.cancer.gov/types/common-cancers>
- G. C. Jayson, et al., Ovarian cancer. *Lancet* 384, 1376–1388 (2014) DOI: 10.1016/S0140-6736(13)62146-7

## The innovation

10 gene signature as a predictive biomarker for platinum treatment against different cancer types



## Advantages

- Gene quantification step can be performed with high throughput, widespread techniques
- Applicability in different tumor types treated with platinum
- Reduction of treatment costs
- Improvement of patients life quality by avoiding ineffective treatment and potentially serious, useless side effects

## What we are looking for

Commercial partner interested in the development of the kit under license or co-development


## Patent application number

102019000000130 (priority: 2019)



## Publication \*

Sonego et al., *Sci. Adv.* 5(5), eaav3235 (2019)  
DOI: 10.1126/sciadv.aav3235



Lucia Coral PhD Knowledge Transfer Manager  
[lucia.coral@cro.it](mailto:lucia.coral@cro.it) 0434659749

Ermes Mestroni Technology Transfer Manager  
[emestroni@cro.it](mailto:emestroni@cro.it) 0434659723